Date: 2015-09-22
Type of information: Construction of a production plant
Compound: manufacturing plant for FlexPen® prefilled devices in Iran
Company: Novo Nordisk (Denmark) Food and Drug Administration of the Islamic Republic of Iran (Iran)
Therapeutic area: Metabolic diseases
Type agreement: construction of a production plant
Action mechanism:
Disease: diabetes
Details: * On September 22, 2015, Novo Nordisk announced that Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen® prefilled devices in Iran. The project is expected to last five years and represents a Novo Nordisk investment of approximately € 70 million. The production will function in compliance with Good Manufacturing Practices (GMP), which will ensure the quality and reliability of the products. With construction of the new facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs around 130 people in Iran.
Financial terms:
Latest news:
